GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensysce Biosciences Inc (NAS:ENSC) » Definitions » Tangible Book per Share

Ensysce Biosciences (Ensysce Biosciences) Tangible Book per Share : $0.51 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ensysce Biosciences Tangible Book per Share?

Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. Ensysce Biosciences's tangible book value per share for the quarter that ended in Mar. 2024 was $0.51.

Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Ensysce Biosciences Tangible Book per Share Historical Data

The historical data trend for Ensysce Biosciences's Tangible Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ensysce Biosciences Tangible Book per Share Chart

Ensysce Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Tangible Book per Share
-63.68 -76.72 -6.95 -0.10

Ensysce Biosciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Tangible Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 1.54 0.52 -0.10 0.51

Competitive Comparison of Ensysce Biosciences's Tangible Book per Share

For the Biotechnology subindustry, Ensysce Biosciences's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ensysce Biosciences's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ensysce Biosciences's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Ensysce Biosciences's Price-to-Tangible-Book falls into.



Ensysce Biosciences Tangible Book per Share Calculation

Ensysce Biosciences's Tangible Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(-0.323-0-0)/3.14608
=-0.10

Ensysce Biosciences's Tangible Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(3.749-0-0)/7.32917
=0.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Ensysce Biosciences  (NAS:ENSC) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Ensysce Biosciences Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of Ensysce Biosciences's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Ensysce Biosciences (Ensysce Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
7946 Ivanhoe Avenue, Suite 201, La Jolla, CA, USA, 92037
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the?Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform.
Executives
Bob G Gower director 402 TIMBERWILDE LANE, HOUSTON TX 77024
Lynn Kirkpatrick director, officer: Chief Executive Officer 110 110TH AVENUE NE, SUITE 685, BELLEVUE WA 98004
Nilab Osman officer: Chief Medical Officer C/O ENSYSCE BIOSCIENCES, INC., 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Lee M. Rauch director C/O ENSYSCE BIOSCIENCES, INC., 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Linda Pestano officer: Chief Development Officer 7946 IVANHOE AVENUE, LA JOLLA CA 92037
Kevin Geoffrey Birkett officer: Chief Commercial Officer 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
William K Schmidt officer: Chief Medical Officer TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
David Carl Humphrey officer: Chief Financial Officer 4767 NEXUS CENTRE DR, SAN DIEGO CA 92121
William H Chang director, 10 percent owner C/O SEMLER SCIENTIFIC, INC., 911 BERN COURT, SUITE 110, SAN JOSE CA 95112
Andrew Benton director 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Adam Levin director 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Jeffrey Millard officer: Chief Operating Officer 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Richard Chester Wright officer: Chief Business Officer 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Steven Robert Martin director 11011 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Curtis Rosebraugh director 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037